DX-88 and HAE: a developmental perspective.

@article{Williams2003DX88AH,
  title={DX-88 and HAE: a developmental perspective.},
  author={Anthony Williams and Lynn G Baird},
  journal={Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis},
  year={2003},
  volume={29 3},
  pages={255-8}
}
An example of an approach to the developmental philosophy of novel recombinant products is explored by using the exemplar of Hereditary Angioedema (HAE). Plasma kallikrein is believed to be an important mediator of angioedema in patients with genetic deficiency of C1 esterase inhibitor (HAE patients). DX-88, a novel Kunitz domain produced by phage display (a powerful method of generating novel binders to potentially therapeutic targets), is a potent and selective inhibitor of plasma kallikrein… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Selective inhibition of plasma kallikrein protects brain from reperfusion injury.

The Journal of pharmacology and experimental therapeutics • 2006
View 4 Excerpts
Highly Influenced

Conestat alfa for the treatment of angioedema attacks

Therapeutics and clinical risk management • 2011
View 3 Excerpts
Highly Influenced

Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

International journal of biochemistry and molecular biology • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…